Seaport Therapeutics, Inc. Common Stock (SPTX) Stock Price

Seaport Therapeutics, Inc. Common Stock Price

NYSE·CLOSED
17.76
​
Market closed

Analysts set a median price target of 50.00 USD, implying 181.5% above the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus.

Seaport Therapeutics, Inc. Common Stock stock price

Access this data via the Eulerpool API

Seaport Therapeutics, Inc. Common Stock business model & stock analysis

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts.

Frequently asked questions about Seaport Therapeutics, Inc. Common Stock

Analysts currently set an average price target of 43.33 USD for the Seaport Therapeutics, Inc. Common Stock stock (median: 50.00 USD), implying +144.0 % versus the latest price. The consensus is based on 13 analyst ratings.

13 analysts currently rate the Seaport Therapeutics, Inc. Common Stock stock: 11 recommend buying, 2 holding and 0 selling.

Converted at the current exchange rate, the Seaport Therapeutics, Inc. Common Stock share trades at 15.90 EUR (17.76 USD).

The revenue cannot currently be calculated for Seaport Therapeutics, Inc. Common Stock.

The expected profit of Seaport Therapeutics, Inc. Common Stock is -315.85 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Seaport Therapeutics, Inc. Common Stock is currently -2.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Seaport Therapeutics, Inc. Common Stock stock.

The P/S cannot be calculated for Seaport Therapeutics, Inc. Common Stock currently.

The Eulerpool Quality Score for Seaport Therapeutics, Inc. Common Stock is 2/10.

The ISIN of Seaport Therapeutics, Inc. Common Stock is US81221K1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Seaport Therapeutics, Inc. Common Stock is SPTX. The ticker symbol is used to trade Seaport Therapeutics, Inc. Common Stock shares on the stock exchange.

Fair ValueTerminal
17.23 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
-
Industry
N/A
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
May 1, 2026
ISIN
US81221K1088
Market capitalization
950.70 M USDSmall Cap
52-Week Range
PEG
0.58
P/E ratio
P/Ee 2026
-2.17
P/Ee 2027
-4.98
P/Ee 2029
-5.37
P/Ee 2030
-4.35
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
82.37 %
Last updated Oct 13, 2026, 7:58 PM

Seaport Therapeutics, Inc. Common Stock Peer Group